Pfizer Inc. and partner BioNTech SE have submitted data to U.S. health regulators needed to clear a Covid-19 booster shot among the general public.

The companies said Monday they sent to the U.S. Food and Drug Administration results from a small, early-stage study showing a third dose of their vaccine generated higher levels of neutralizing antibodies against the original virus and against the Beta and Delta variants than the standard two-dose regimen.

The addition of the third dose also appeared safe in the trial, the companies said.

Given the immune response boost from a third dose, the companies said, a booster shot within six months to a year after the second shot might help maintain protection against symptomatic Covid-19.

Pfizer and BioNTech are also conducting a larger late-stage study evaluating whether a third dose safely provides more protection. The companies said they expect those results shortly and will then submit the data to the FDA.

This post first appeared on wsj.com

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

People named Josh battle it out with pool noodles in Nebraska to find the top Josh

Hundreds of people named Josh showed up to a park in Lincoln,…

Fishermen using sonar equipment find car at bottom of Illinois river connected to 1976 cold case disappearance

Fishermen using sonar equipment located a vehicle at the bottom of an…

Less Meeting, More Meditation

People exercise inside hearts and circles at Dolores Park in San Francisco…

U. of Oregon apologizes for “despicable chants” at Saturday football game

A representative for the University of Oregon apologized on Saturday after video…